Plasma circulating tumor deoxyribonucleic acid methylation enables noninvasive disease stratification beyond prostate-specific antigen in prostate cancer.
Blood methylation signatures can accurately distinguish limited prostate cancer from metastatic disease, helping guide treatment intensity.
BACKGROUND: Accurate discrimination between localized and metastatic prostate cancer (PCa) remains a critical unmet need in clinical practice, particularly in patients with equivocal imaging findings or biologically high-risk disease. METHODS: A total of 174 patients were included, comprising localized PCa ( RESULTS: Plasma methylation levels of C2orf88 and HAPLN3 increased significantly with advancing disease stage ( CONCLUSIONS: A two-marker ctDNA methylation signature enables accurate discrimination between localized and metastatic PCa.
What the study was
- Study design
- Observational biomarker study
- Population
- Prostate cancer patients, localized vs metastatic (n=174)
- Sample size
- 174
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Prostate international
Why it surfaced
ctDNA methylation markers for non-invasive prostate cancer staging/stratification with clinical utility beyond PSA; addresses unmet need for accurate disease-state discrimination.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.